MTRI — Mentari Therapeutics Share News
0.000.00%
Last trade - 00:00- $802.28m
- $801.14m
Brief: InMed To Supply Rare Cannabinoids To Radicle Science’S “Radicle Energy Study”
Brief: InMed Advances Collaboration Agreement with Leading Cannabinoid Research Expert
Brief: InMed Pharmaceuticals Files Prospectus Relates To Offering And Resale By Selling Shareholders Of Up To 6.1 Million Of Common Shares
Brief: InMed Announces Management Changes
InMed Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Inmed Pharmaceuticals Reports $0.31 Loss Per Share In Second Quarter Fiscal 2022
InMed Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Inmed Pharmaceuticals - Files Preliminary Prospectus Relating To Offering And Resale By Selling Shareholder Of Up To 2.1 Million Of Co's Shares
Brief: InMed Pharmaceuticals Announces Publication Of Peer-Reviewed Article On The Use Of Cbn As A Potential Treatment For Glaucoma
InMed Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results
InMed Pharmaceuticals Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: InMed Pharmaceuticals Announces Commencement Of Phase 2 Clinical Trial Investigating Cannabinol In The Treatment Of Epidermolysis Bullosa
NASDAQ RESUMED AT 09:53 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:49 AM
U.S. STOCKS ON THE MOVE-Zivo Bioscience, Accenture, Carnival Corp
InMed Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
InMed Pharma gains on narrower-than-expected loss
InMed Pharmaceuticals Inc expected to post a loss of 34 cents a share - Earnings Preview